Despite permissive product labels in advanced disease, VEGFR TKIs do appear less active in non-ccRCC [28], and we caution against extrapolation of the findings of NAXIVA to patients in whom there is not pre-treatment histological proof of ccRCC. The gene discussed is KDR; the disease is nonpapillary renal cell carcinoma.